PharmaEssentia announced that its revenue for June reached NT$1.2 billion, marking a 1.51% month-on-month increase and a 41.09% year-on-year growth. The revenue was primarily driven by steady sales growth of its novel rare blood cancer treatment, Ropeginterferon alfa-2b (Ropeg, also known as P1101), in the U.S. market. Despite the recent strength of the New Taiwan Dollar, the company still posted both monthly and yearly revenue gains, supporting continued revenue growth.
In the second quarter of 2025, PharmaEssentia’s revenue exceeded NT$3.6 billion, reflecting a 10.6% increase over the first quarter and a 56.19% year-on-year rise. This marked the ninth consecutive quarter of record-high revenue. Cumulative revenue for the first half of 2025 reached NT$6.86 billion, a 73.23% increase compared to the same period last year, highlighting the strong global demand for Ropeg and the company’s robust growth momentum.
PharmaEssentia has also made notable progress in its global market expansion. Ropeg has received pricing approval from Brazil’s drug pricing authority (CMED), with the approved price for the 500 mcg/mL formulation set at US$4,000. The company plans to begin supplying the Brazilian market in the third quarter, further strengthening its presence in Latin America.
Progress is also accelerating in the development of new indications. PharmaEssentia is actively pursuing regulatory approval for Ropeg to treat essential thrombocythemia (ET). The company has already submitted a marketing authorization application to China’s National Medical Products Administration (NMPA) and plans to file similar applications in Taiwan, the United States, Japan, and other markets within the year. Pre-marketing preparations are also underway, positioning ET as the next key growth driver for the company.
In addition, PharmaEssentia has formally submitted a request to the U.S.-based National Comprehensive Cancer Network (NCCN) to include Ropeg as a recommended treatment option for ET patients in its clinical practice guidelines. If successful, this could accelerate insurance coverage for Ropeg in ET treatment, including prioritized reimbursement, ultimately benefiting a broader patient population.
The application for the ET indication is based on the breakthrough results from the global Phase 3 trial, “SURPASS ET,” evaluating Ropeg in ET treatment. The trial demonstrated that patients in the Ropeg arm had a significantly higher durable clinical response rate compared to those receiving Anagrelide (42.9% vs. 6.0%; p=0.0001), reaching statistical significance. These findings were presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where the study was selected as one of the “Best of ASCO” featured abstracts. It was also chosen as one of the top six abstracts for presentation during the Plenary Session—the highest honor—at the European Hematology Association (EHA) Annual Congress.
These prestigious recognitions from two leading international conferences have brought widespread attention and enthusiastic response from the global academic community and the medical field specializing in myeloproliferative neoplasms (MPNs), further underscoring the importance and impact of the SURPASS ET trial.
Resource: 藥華藥6月營收雙增，Q2營收連九季刷新高，上半年營收年增73.23%
